Fosbøl, M.Ø.; Mortensen, J.; Petersen, P.M.; Loft, A.; Madsen, J.; Kjaer, A.
uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study. Diagnostics 2021, 11, 1087.
https://doi.org/10.3390/diagnostics11061087
AMA Style
Fosbøl MØ, Mortensen J, Petersen PM, Loft A, Madsen J, Kjaer A.
uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study. Diagnostics. 2021; 11(6):1087.
https://doi.org/10.3390/diagnostics11061087
Chicago/Turabian Style
Fosbøl, Marie Øbro, Jann Mortensen, Peter Meidahl Petersen, Annika Loft, Jacob Madsen, and Andreas Kjaer.
2021. "uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study" Diagnostics 11, no. 6: 1087.
https://doi.org/10.3390/diagnostics11061087
APA Style
Fosbøl, M. Ø., Mortensen, J., Petersen, P. M., Loft, A., Madsen, J., & Kjaer, A.
(2021). uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study. Diagnostics, 11(6), 1087.
https://doi.org/10.3390/diagnostics11061087